Centralized monitoring of clinical safety of troxerutin and cerebroprptein Injection after marketing in hospital

Status

Active, not recruiting

Phases

Phase 4

Study type

Observational

Source

ChiCTR

Registry ID

ChiCTR2000034875

Enrollment

Unknown

Registered

2020-07-22

Start date

2020-09-01

Completion date

Unknown

Last updated

2020-07-27

For informational purposes only — not medical advice. Sourced from public registries and may not reflect the latest updates. Terms

Conditions

ADR/ADE

Interventions

Treatment group:The administration of troxerutin and cerebroprptein Injection

Eligibility

Sex/Gender

All

Inclusion criteria

Inclusion criteria: All hospitalized patients were treated with compound tripeptide injection.

Exclusion criteria

Exclusion criteria: Inpatients who were unable to collect the information needed for this study.

Design outcomes

Primary

Measure	Time frame
ADR/ADE;	—

Countries

China

Contacts

Public ContactXuelin Li

The First Affiliated Hospital of Henan University of Chinese Medicine

lixuelin450000@163.com+86 13703711133

Outcome results

None listed

Source: ChiCTR (via WHO ICTRP) · Data processed: Feb 4, 2026